Galmed Pharmaceuticals Ltd. (GLMD)
NASDAQ: GLMD · Real-Time Price · USD
0.6700
+0.0046 (0.69%)
At close: Feb 3, 2026, 4:00 PM EST
0.7000
+0.0300 (4.48%)
After-hours: Feb 3, 2026, 5:09 PM EST

Galmed Pharmaceuticals Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Sep '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
Selling, General & Admin
3.263.33.924.665.664.13
Research & Development
3.852.983.571327.2226.08
Operating Expenses
7.116.287.4917.6532.8830.21
Operating Income
-7.11-6.28-7.49-17.65-32.88-30.21
Interest Expense
-0.61-0.61----
Interest & Investment Income
0.670.50.380.30.561.19
Currency Exchange Gain (Loss)
0.040.04-0.040.04-0.03-0.12
Other Non Operating Income (Expenses)
-0.02-0.020.25-0.02-0.04-0.03
EBT Excluding Unusual Items
-7.03-6.36-6.9-17.34-32.39-29.17
Gain (Loss) on Sale of Investments
-1.67-1.16-0.01-0.53-0.080.4
Pretax Income
-8.7-7.52-6.91-17.87-32.47-28.77
Net Income
-8.7-7.52-6.91-17.87-32.47-28.77
Net Income to Common
-8.7-7.52-6.91-17.87-32.47-28.77
Shares Outstanding (Basic)
310000
Shares Outstanding (Diluted)
310000
Shares Change (YoY)
474.24%303.31%65.23%2.22%15.59%0.79%
EPS (Basic)
-2.71-8.08-29.95-127.90-237.59-243.35
EPS (Diluted)
-2.71-8.08-29.95-127.90-237.59-243.35
Free Cash Flow
-6.28-5.88-6.14-18.51-32.9-26.33
Free Cash Flow Per Share
-1.96-6.32-26.59-132.48-240.78-222.72
EBITDA
-7.05-6.2-7.46-17.62-32.84-30.17
D&A For EBITDA
0.060.080.030.040.040.04
EBIT
-7.11-6.28-7.49-17.65-32.88-30.21
Updated Nov 26, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q